Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in ...
BLA Filing Based on HARMONi Global Phase III Study Results PDUFA Goal Action Date of November 14, 2026 Significant Unmet Need Remains; Over 14,000 U.S. Patients Eligible for Treatment Each Year in This Setting Summit Therapeutics Inc. (NASDAQ: SMMT) (…